Perspective Therapeutics updates corporate presentation highlighting pipeline progress and clinical data

Perspective Therapeutics, Inc.

[212Pb]VMT-α-NET Phase 1/2a for neuroendocrine tumors shows anti-tumor activity with no renal decline.
Melanoma program [212Pb]VMT01 Phase 1/2a ongoing; safety profile detailed in presentation.
PSV359 targeting FAP-α active on tumor and stroma; pre-targeting platform also described.
On-demand order fulfillment at regional sites as part of supply chain and manufacturing infrastructure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.